Status:
UNKNOWN
Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients
Lead Sponsor:
S-Evans Biosciences Co., Ltd.
Collaborating Sponsors:
Zhejiang University
Wenzhou Medical University
Conditions:
Type 1 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to investigate whether the treatment of human menstrual blood-derived mesenchymal stem cells which would be applied to diabetes patients is safe and effective.
Detailed Description
Diabetes mellitus is chronic metabolic diease caused by absent or rejection insulin from pancreatic b cells.The traditional treatment strategies for diabetes are daily injections with insulin and tran...
Eligibility Criteria
Inclusion
- male and female patients at the age of 18 to 75.
- agreement to receive written informed consent.
- voluntary submission to the procedures of the study protocol.
- clinical diagnosis is classified to type 1 diabetes(T1DM).
- T1DM duration ≥ 1 and ≤ 20 years from the time of enrollment.
Exclusion
- renal dysfunction, eye disease or other organ disease.
- cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in past 6 months.
- pregnancy
- mental disorders
- hepatitis C, HIV, RPR,active tuberculosis or blood diseases
- any malignancy
- any other severe diseases that could potentially influence the infusion results
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01496339
Start Date
January 1 2012
End Date
May 1 2014
Last Update
June 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310003